Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs.
Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration s accelerated approval pathway for pharmaceuticals that target urgent medical needs.
A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence that some work.